Child Leprosy in India: Why Elimination Was Not the End

India reported 3,832 new leprosy cases among children in financial year 2025 to 2026, the largest absolute child caseload in WHO’s latest global update. The report is labelled “2025”, but explicitly uses April 2025 to March 2026 data for India. An absolute case count should not be confused with the highest population adjusted rate. (WHO global update)

The Health Ministry’s annual report records 91,783 new cases overall, including 37 children with Grade 2 Disability. These figures make early diagnosis and prevention of disability central to the discussion. (NLEP annual report)

For UPSC, the issue connects three distinct outcomes: reducing disease prevalence, interrupting transmission and protecting the rights of affected people.

What Does “91.6% Above Target” Mean?

The National Strategic Plan and Roadmap for Leprosy had projected 2,000 new child cases for 2025 to 2026. The recorded 3,832 cases exceed that benchmark by 1,832, or 91.6%. This is a comparison with a programme projection, not a 91.6% increase over the previous year. (National strategic plan)

For 2026 to 2027, the roadmap projects 1,000 child cases and an all age G2D rate of 0.5 per million people. The latter should not be confused with the separate disability rate calculated for children. (Roadmap projections)

The observed all age G2D rate in 2025 to 2026 was 1.34 per million. The gap identifies the scale of change required; it does not, by itself, prove that every future target is impossible. (NLEP annual report)

Elimination Was a Threshold, Not Eradication

India achieved national elimination of leprosy as a public health problem in 2005, defined as registered prevalence below one case per 10,000 people. That was a specified epidemiological milestone, not a declaration that transmission had stopped. (DGHS programme overview)

Registered prevalence counts people recorded as needing treatment at a particular time. Annual new case detection counts diagnoses over a year. A low value for the first can coexist with thousands of new diagnoses.

At the end of March 2026, India’s registered prevalence was 0.56 per 10,000. That remains below the historical threshold despite continuing case detection. (NLEP annual report)

Elimination as a public health problem, interruption of transmission and eradication are different endpoints. Eradication means a permanent worldwide reduction to zero new infections through deliberate efforts, rather than meeting a national prevalence threshold. (CDC explanation of elimination and eradication)

For an exam answer, specify the disease, geographical area, indicator and definition whenever using the word “elimination”.

Why Child Cases Matter for Transmission

WHO treats new cases among children younger than 15 as an indicator of recent transmission. Childhood limits the period during which infection could have occurred, making these cases important for investigating continuing exposure. (WHO global update)

However, “recent” does not necessarily mean the same financial year. The bacteria grow slowly, and symptoms can take years to appear, sometimes up to 20 years after exposure. A diagnosis date is not an infection date. (CDC disease overview)

Child cases support further investigation of undetected infection among contacts. They do not identify a particular adult as the source, or prove that transmission happened at school.

Grade 2 Disability means visible impairment and is used as an indicator of delayed detection. It is not simply another name for having leprosy. (WHO disability indicators)

An investigation can examine when symptoms were noticed, whether earlier consultations occurred and where referral or treatment was delayed. This separates evidence about a care pathway from assumptions about individual blame.

The 2027 Roadmap Has a District Level Clock

The national roadmap seeks interruption of transmission at district level, evidenced by five consecutive years without a new indigenous child case. “Indigenous” distinguishes locally acquired infection from an imported case. (National strategic plan)

Consequently, a district reporting a locally acquired child case cannot immediately establish a completed five year period without such cases. National totals, however, do not reveal the status of every district.

Surveillance also changes what the figures show. The programme’s annual report attributes increases during earlier years partly to extensive household surveys that detected previously unrecognised cases. (NLEP annual report)

A short term rise following better screening need not mean transmission suddenly increased. Equally, fewer reported cases cannot demonstrate success if screening weakened. Interpretation requires information about how cases were sought.

The Disease Is Curable, but Timing Matters

Leprosy, also called Hansen disease, is a neglected tropical disease caused mainly by the bacterium Mycobacterium leprae. It affects the skin and peripheral nerves. Untreated disease can cause lasting disability, while early treatment can prevent it. (WHO factsheet)

WHO recommends multidrug therapy using rifampicin, dapsone and clofazimine. The recommended duration is six months for paucibacillary disease and 12 months for multibacillary disease. Treatment classification and prescribing require clinical assessment. (WHO treatment guidance)

The disease is associated with prolonged, close contact with an untreated person. It does not spread through ordinary casual contact such as handshakes, hugs or sharing meals. WHO states that transmission stops when treatment begins. (WHO transmission guidance)

These distinctions matter for school attendance and family life. Fear of everyday contact is not a substitute for an informed medical assessment.

Free Medicines and Last Mile Access Are Different

The National Leprosy Eradication Programme is a centrally sponsored scheme under the National Health Mission. It provides free prevention, diagnosis, treatment and rehabilitation through public health facilities. (DGHS programme overview)

That arrangement identifies the services the programme provides. Evaluating actual access requires additional questions: was the condition recognised, was a trained clinician available, could the family reach the facility, and was treatment completed?

Consider a hypothetical child whose skin patch is repeatedly treated without checking sensation. Medicine availability would not resolve the diagnostic delay until the condition was correctly assessed. CDC identifies altered skin patches and loss of sensation among the findings clinicians examine. (CDC diagnostic overview)

Care may also continue after antimicrobial treatment. Rehabilitation, management of nerve damage and support for participation address needs that are different from killing the bacteria. (NLEP services)

The new case tally cannot quantify how many infections remain undetected. Describing a precise “last 10,000 hidden cases” would require a separate estimate and methodology.

Contact Tracing Needs a Clear Denominator

Contact screening and single dose rifampicin preventive treatment for eligible contacts are existing programme measures. Eligibility assessment excludes active disease and relevant contraindications; this is not a medicine for unsupervised household use. (NLEP contact tracing framework)

The annual report states that 91.16% of contacts found eligible received preventive treatment in 2025 to 2026. That percentage measures delivery among identified eligible contacts. It does not establish that every exposed person in the community was identified. (NLEP coverage data)

This is a useful governance distinction: coverage within a register and completeness of the register are different questions.

Digital surveillance through Nikusth 2.0 supports case recording and monitoring. (DGHS programme overview)

An assessment can therefore examine contact identification, examination, eligibility, treatment and follow up separately. Confidentiality also matters: contact tracing should not become public labelling of a child or family.

Discrimination Is a Health Governance Issue

WHO identifies stigma and discrimination as barriers to diagnosis, treatment and participation. Its 2026 work on patient involvement includes women, children, persons with disabilities and migrants. (WHO participation initiative)

The mechanism is straightforward. A family expecting exclusion may see disclosure as carrying a social cost. Drug availability alone does not remove that concern.

In Report No. 256, published in April 2015, the Law Commission proposed the Eliminating Discrimination Against Persons Affected by Leprosy Bill, 2015. Its model covered discrimination and access to healthcare, education, housing and employment. A proposed model is not an enacted law. (Law Commission report)

The often quoted 119 discriminatory provisions relates to the later litigation brought by Vidhi Centre for Legal Policy. A July 2026 account by The Leprosy Mission Trust India traces that challenge to 2017. It is not a verified current count of 119 unchanged laws. (Legal reform account)

Legal changes have occurred. The Personal Laws (Amendment) Act, 2019 removed leprosy related provisions from five personal laws, including grounds for divorce under specified marriage laws. (Text of the Act)

In Pankaj Sinha v. Union of India, 2018, the Supreme Court directed governments to ensure free drug availability, nondiscriminatory healthcare, rehabilitation and protection against school exclusion of children from affected families. The judgment connected the issue with equality and dignity. (Supreme Court judgment)

For GS II, examine Articles 14 and 21 alongside these documented directions. Avoid assuming that one judgment automatically removed every discriminatory provision.

The 2015 model bill is documented, but the sources reviewed do not establish the introduction or current pending status of the separately cited Persons Affected by Leprosy (Welfare Provisions) Bill, 2022.

What an Assessment of Progress Can Measure

Case counts describe part of the outcome. An evaluation can also examine time to diagnosis, disability at detection, continuity of medicines, completed referrals and whether children remain in education.

A programme might record successful treatment while a family still faces exclusion. These outcomes need separate measures.

WHO’s guidance on participation supports involving affected people in service design and decision making, rather than treating them only as recipients of care. (WHO participation guidelines)

For the Centre State coordination dimension, read PrepAiro’s explanation of cooperative federalism and Centre State relations.

How to Use Child Leprosy in UPSC Mains

For GS II, connect public health delivery, social justice, constitutional rights and accountability. For GS III, explain bacterial disease, multidrug therapy and surveillance. For Essay, distinguish a measurable administrative milestone from the lived experience of receiving care.

A practice question could be:

“Distinguish elimination as a public health problem from interruption of transmission. Using child leprosy cases, examine the relationship between surveillance, timely treatment and social inclusion.”

Build the answer around definitions, dated evidence, service delivery and rights. Do not treat a target gap as a year on year growth rate.

The central lesson is that low registered prevalence does not establish zero transmission. Detecting infection, preventing disability and ensuring equal participation are related tasks, but none can stand in for the others.